tirzepatide discord Injection for Seniors with Medicare Personalized Tirzepatide Treatment

The SURMOUNT-5 trial (Aronne et al., NEJM 2025) showed that tirzepatide, a dual GIPGLP-1 receptor agonist, outperforms semaglutide in reducing weight and cardiometabolic risk in adults with obesity without diabetes

If youre exploring options for managing your health, GLP-1 patches are an excellent alternative to traditional methods.

Henry Meds reviewed: business model, clinical structure, and how the program compares to PlexusDx Weight Management Protocols

Let's find out from FitterFly Experts!

According to the 2024 World Obesity Report, the global prevalence of obesity is steadily increasing, with projections indicating that by 2035, over half of the world's population will be classified as overweight [1]

The SURPASS clinical trial program has been investigating the effectiveness and safety of tirzepatide in patients with type 2 diabetes